Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 6/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.54 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28580283 | 0.88 | GSR (0.43) | — | |
| SCHEMBL191235 | 0.84 | NOS3 (0.41) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL490891 | 0.84 | NOS3 (0.41) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL191236 | 0.84 | NOS3 (0.41) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL18019367 | 0.80 | SLC1A2 (0.33) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL16798436 | 0.77 | SLC1A2 (0.40) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL9989984 | 0.76 | GPR84 (0.43) | — | |
| SCHEMBL9989980 | 0.76 | GPR84 (0.43) | — | |
| SCHEMBL10314812 | 0.74 | NOS3 (0.38) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 | |
| SCHEMBL20591675 | 0.74 | NOS3 (0.38) | SLC1A1SLC1A2SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012150204-A1 | NOVEL PRECURSORS OF GLUTAMATE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-11-08 | — | — | WO | disclosed |
| EP-2520557-A1 | Novel precursors of glutamate derivatives | Bayer Pharma Aktiengesellschaft (DE) | 2012-11-07 | — | — | EP | disclosed |